WuXi Biologics WKN: A2QJCN ISIN: KYG970081173 Forum: Aktien User: Summer.76

WuXi Biologics (02269 HK) gains JPMorgan Chase’s increase of 1,025,564 shares https://www.finet.hk/newscenter/news_content/60af73128ac02a2b501035fe According to the equity information of the Hong Kong Stock Exchange, WuXi Biologics (02269 HK) was acquired by JPMorgan Chase on May 24 at an average price of HK$108.6527 per share to increase its holdings of 1.025 million shares, involving approximately 111 million shares. Hong Kong dollar. After the increase, JPMorgan Chase’s latest shareholding number is 381 million shares, and the shareholding ratio has increased from 8.99% to 9.02%.

👍🏼

WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership https://finance.yahoo.com/news/wuxi-biologics-oncoc4-establish-exclusive-003000473.html ...today announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biologics including its late-stage project, ONC-392, a next generation CTLA-4 antibody which is under phase I clinical trials in the U.S. and China.  ...

Ja stimmt, ich bin aber voll investiert,,😉😉

Was ein klasse Unternehmen. Irgendwie traurig, dass es in Deutschland bzw. Europa so unbekannt ist 🤷‍♂️

WuXi Biologics (2269 HK) rose 6%, survey minutes revealed that this year's revenue and net profit growth rate is around 50% https://m.jrj.com.cn/madapter/hk/2021/05/25140632816219.shtml WuXi Biologics (2269 HK), which was selected as one of the top ten core potential assets of Gelonghui in 2021 "Betting on China", was significantly stronger today. It rose 6.01% to 116.4 Hong Kong dollars during the day, and its market value Approaching 490 billion Hong Kong dollars. A summary of WuXi Biologics’ research and exchanges revealed: “The company’s revenue contribution from CMO projects and the number of projects will increase significantly this year. It is conservatively estimated that there will be 6 CMO projects this year, excluding other orders that may be obtained from outside. The company’s feedback to the market is that this year’s revenue and net profit have increased by about 50% year-on-year."

The HSI opens 0.14% lower https://www.hstong.com/news/detail/21052409250171076 According to news on May 24, US stocks closed mixed on Friday. The decline in Bitcoin dragged down technology stocks and the Nasdaq. The S&P index recorded a second consecutive week of decline. At today's opening, the Hang Seng Index opened lower by 0.14% to 28417.99 points; the State-owned Enterprise Index fell 0.5%, the red chip index fell 0.09%, and the Hang Seng Technology fell 0.8%.

Healthcare Gains Drive Chinese Stocks Even Higher https://www.etftrends.com/china-insights-channel/healthcare-gains-drive-chinese-stocks-higher/amp/

Bearish block trade of WUXI BIO(02269) 393.5K shares at $109.9, $43.246M turnover http://www.aastocks.com/en/stocks/news/aamm-content/aat21052086/block-traded

u.a. WuXi Bio: Investitionen in Gesundheitsunternehmen aus Schwellenländern liegen im Trend. Welche Geschäftsmodelle besonders im Fokus stehen, erklärt Andreas Scharf, Analyst bei Apo Asset Management. https://www.dasinvestment.com/diese-gesundheitsunternehmen-stechen-hervor/

WuXi finanziert mit: https://www.prnewswire.com/news-releases/duality-biologics-completed-90-million-series-b-financing-301294736.html (Duality Biologics Completed $90 Million Series B Financing)

Feiertag heute in HK

WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services https://www.prnewswire.com/news-releases/wuxi-biologics-and-wuxi-sta-jointly-established-wuxi-xdc-to-provide-fully-integrated-bioconjugate-cdmo-services-301291101.html

https://pub.webull.com/us/news-html/2ed113b12bcb49b085ae65c65dce183b.html?theme=2&_v=1&color=1&hl=en&sp=1&_v=1&theme=2&color=1&hl=en BRIEF-Shanghai Hile Bio-Tech, WuXi Biologics To Subscribe to Private Share Placement Of WuXi Vaccines

Summer.76 👍🏼